Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Viatris Inc (VTRS) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance

Viatris IncTrade
YieldMax Universe Fund of Option Income ETFsTrade

Price performance (Past 24H)

Key statistics

Viatris Inc vs YieldMax Universe Fund of Option Income ETFs — how do they compare? Viatris Inc trades at $16.45 (market cap $19.09B), while YieldMax Universe Fund of Option Income ETFs trades at $7.53. The key difference: Viatris Inc pays a 2.89% dividend while YieldMax Universe Fund of Option Income ETFs pays none, and Viatris Inc is trading nearer its 52-week high, YieldMax Universe Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.

VTRSYMAX
Market Cap
$19.09B
Sector
HealthIncome / Options Overlay
52-Week High
$17.86$13.14
52-Week Low
$9.49$7.27
Enterprise Value
$31.21B
Dividend Yield
2.89%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Viatris Inc

Viatris (VTRS) trades at $16.61, down 1.6% over the past 24 hours. The stock exhibits a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company reported a net loss of $3.51 billion in 2025 despite revenue of $14.30 billion, though recent quarters have shown earnings beats. Positive cash flow generation and a dividend payment highlight financial stability, while analyst sentiment is mixed with a majority hold rating.

The outlook for VTRS hinges on its ability to return to profitability and sustain operational improvements. Investment opportunities include strong cash flow, deleveraging progress, and pipeline developments, but risks involve persistent net losses, competitive pressures, and potential regulatory impacts from proposed generic drug tariffs.

YieldMax Universe Fund of Option Income ETFs

YMAX trades at $7.70 with a slight 0.13% daily gain, showing modest positive momentum. The technical outlook is bullish with moving averages supporting upward movement, though oscillators remain neutral. Recent news highlights the fund's weekly dividend distributions but also raises concerns about NAV erosion and sustainability of the high-yield strategy. The fund's structure as a fund-of-funds adds layers of costs that impact overall returns.

YMAX faces significant challenges with declining share price despite high distributions, suggesting the current yield may be unsustainable. The fund's principal erosion and structural cost issues present substantial risks for income-focused investors. While technical indicators show short-term bullish signals, fundamental concerns about the distribution policy and NAV performance warrant cautious consideration for long-term investment viability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS

About YieldMax Universe Fund of Option Income ETFs

YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.

Read more on YMAX